{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T04:02:50Z","timestamp":1747454570833,"version":"3.40.5"},"reference-count":30,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Abuse of androgenic anabolic steroids (AAS) is associated with a range of cardiovascular side effects, summarized in this review. Apart from being linked to cardiovascular risk factors such as hypertension and dyslipidaemia, AAS abuse is associated with coronary atherosclerosis and imparts a pro-coagulative state, predisposing to thromboembolic disease. Finally, AAS abuse leads to left ventricular hypertrophy and dysfunction, which can ultimately result in heart failure. However, evidence is scarce, and further studies are needed to guide the optimal follow-up and treatment for these patients.<\/jats:p>","DOI":"10.61409\/v04240260","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T13:46:53Z","timestamp":1730900813000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Anabolic steroids and cardiovascular morbidity"],"prefix":"10.61409","author":[{"given":"Josefine","family":"Windfeld-Mathiasen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tor","family":"Biering-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flemming Javier","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"unstructured":"Drugs@FDA: FDA-Approved Drugs. www.accessdata.fda.gov\/scripts\/cder\/daf\/ (11. okt 2023)","key":"ref0"},{"doi-asserted-by":"publisher","unstructured":"Nieschlag E, Vorona E. MECHANISMS IN ENDOCRINOLOGY: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. Eur J Endocrinol. 2015;173(2):R47-R58. https:\/\/doi.org\/10.1530\/EJE-15-0080","key":"ref1","DOI":"10.1530\/EJE-15-0080"},{"unstructured":"Yesalis CE, Bahrke MS. History of doping in sport. Int Sports Studies. 2003;24(1):42-76.","key":"ref2"},{"doi-asserted-by":"publisher","unstructured":"Sagoe D, Molde H, Andreassen CS et al. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014;24(5):383-98. https:\/\/doi.org\/10.1016\/j.annepidem.2014.01.009","key":"ref3","DOI":"10.1016\/j.annepidem.2014.01.009"},{"unstructured":"Windfeld-Mathiasen J, Christoffersen T, Horwitz H. Bivirkninger ved anabole steroider. Ugeskr L\u00e6ger. 2022;184:V06220373.","key":"ref4"},{"doi-asserted-by":"publisher","unstructured":"Horwitz H, Andersen JT, Dalhoff KP. Health consequences of androgenic anabolic steroid use. J Intern Med. 2019;285(3):333-340. https:\/\/doi.org\/10.1111\/joim.12850","key":"ref5","DOI":"10.1111\/joim.12850"},{"doi-asserted-by":"publisher","unstructured":"Windfeld-Mathiasen J, Christoffersen T, Strand NAW et al. Psychiatric morbidity among men using anabolic steroids. Depress Anxiety. 2022;39(12):805-812. https:\/\/doi.org\/10.1002\/da.23287","key":"ref6","DOI":"10.1002\/da.23287"},{"doi-asserted-by":"publisher","unstructured":"Lincoff AM, Bhasin S, Flevaris P et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. https:\/\/doi.org\/10.1056\/NEJMoa2215025","key":"ref7","DOI":"10.1056\/NEJMoa2215025"},{"doi-asserted-by":"publisher","unstructured":"Nota NM, Wiepjes CM, de Blok CJM et al. Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation. 2019;139(11):1461-1462. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038584","key":"ref8","DOI":"10.1161\/CIRCULATIONAHA.118.038584"},{"doi-asserted-by":"publisher","unstructured":"Westerman ME, Charchenko CM, Ziegelmann MJ et al. Heavy testosterone use among bodybuilders: an uncommon cohort of illicit substance users. Mayo Clin Proc. 2016;91(2):175-82. https:\/\/doi.org\/10.1016\/j.mayocp.2015.10.027","key":"ref9","DOI":"10.1016\/j.mayocp.2015.10.027"},{"doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez-Guerra AI, Tapia J, Men\u00e9ndez-Quintanal LM, Lucena JS. Sudden cardiac death in anabolic androgenic steroids abuse: case report and literature review. Forensic Sci Res. 2019;4(3):267-273. https:\/\/doi.org\/10.1080\/20961790.2019.1595350","key":"ref10","DOI":"10.1080\/20961790.2019.1595350"},{"doi-asserted-by":"publisher","unstructured":"Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP et al. Mortality among users of anabolic steroids. JAMA. 2024;331(14):1229-1230. https:\/\/doi.org\/10.1001\/jama.2024.3180","key":"ref11","DOI":"10.1001\/jama.2024.3180"},{"doi-asserted-by":"publisher","unstructured":"Rasmussen JJ, Schou M, Madsen PL et al. Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma? J Hypertens. 2018;36(2):277-285. https:\/\/doi.org\/10.1097\/HJH.0000000000001546","key":"ref12","DOI":"10.1097\/HJH.0000000000001546"},{"doi-asserted-by":"publisher","unstructured":"Williams B, Mancia G, Spiering W et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","key":"ref13","DOI":"10.1093\/eurheartj\/ehy339"},{"doi-asserted-by":"publisher","unstructured":"Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 2010;106(6):893-901. https:\/\/doi.org\/10.1016\/j.amjcard.2010.05.013","key":"ref14","DOI":"10.1016\/j.amjcard.2010.05.013"},{"doi-asserted-by":"publisher","unstructured":"Smit DL, Grefhorst A, Buijs MM et al. Prospective study on blood pressure, lipid metabolism and erythrocytosis during and after androgen abuse. Andrologia. 2022;54(4):e14372. https:\/\/doi.org\/10.1111\/and.14372","key":"ref15","DOI":"10.1111\/and.14372"},{"doi-asserted-by":"publisher","unstructured":"Chang S, Rasmussen JJ, Frandsen MN et al. Procoagulant state in current and former anabolic androgenic steroid abusers. Thromb Haemost. 2018;118(4):647-653. https:\/\/doi.org\/10.1055\/s-0038-1636540","key":"ref16","DOI":"10.1055\/s-0038-1636540"},{"doi-asserted-by":"publisher","unstructured":"Sidelmann JJ, Gram JB, Rasmussen JJ, Kistorp C. Anabolic-androgenic steroid abuse impairs fibrin clot lysis. Semin Thromb Hemost. 2021;47(1):11-17. https:\/\/doi.org\/10.1055\/s-0040-1714398","key":"ref17","DOI":"10.1055\/s-0040-1714398"},{"doi-asserted-by":"publisher","unstructured":"Coviello AD, Kaplan B, Lakshman KM et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-9. https:\/\/doi.org\/10.1210\/jc.2007-1692","key":"ref18","DOI":"10.1210\/jc.2007-1692"},{"doi-asserted-by":"publisher","unstructured":"Camilleri E, Smit DL, van Rein N et al. Coagulation profiles during and after anabolic androgenic steroid use: data from the HAARLEM study. Res Pract Thromb Haemost. 2023;7(7):102215. https:\/\/doi.org\/10.1016\/j.rpth.2023.102215","key":"ref19","DOI":"10.1016\/j.rpth.2023.102215"},{"doi-asserted-by":"publisher","unstructured":"Baggish AL, Weiner RB, Kanayama G et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991-2002. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.026945","key":"ref20","DOI":"10.1161\/CIRCULATIONAHA.116.026945"},{"doi-asserted-by":"publisher","unstructured":"de Souza FR, Dos Santos MR, Porello RA et al. Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic androgenic steroid users. Atherosclerosis. 2019;283:100-105. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.02.006","key":"ref21","DOI":"10.1016\/j.atherosclerosis.2019.02.006"},{"doi-asserted-by":"publisher","unstructured":"Fyksen TS, Vanberg P, Gjesdal K et al. Cardiovascular phenotype of long-term anabolic-androgenic steroid abusers compared with strength-trained athletes. Scand J Med Sci Sports. 2022;32(8):1170-1181. https:\/\/doi.org\/10.1111\/sms.14172","key":"ref22","DOI":"10.1111\/sms.14172"},{"doi-asserted-by":"publisher","unstructured":"Adami PE, Koutlianos N, Baggish A et al. Cardiovascular effects of doping substances, commonly prescribed medications and ergogenic aids in relation to sports: a position statement of the sport cardiology and exercise nucleus of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2022;29(3):559-575. https:\/\/doi.org\/10.1093\/eurjpc\/zwab198","key":"ref23","DOI":"10.1093\/eurjpc\/zwab198"},{"doi-asserted-by":"publisher","unstructured":"Darke S, Torok M, Duflou J. Sudden or unnatural deaths involving anabolic-androgenic steroids. J Forensic Sci. 2014;59(4):1025-8. https:\/\/doi.org\/10.1111\/1556-4029.12424","key":"ref24","DOI":"10.1111\/1556-4029.12424"},{"doi-asserted-by":"publisher","unstructured":"Rasmussen JJ, Schou M, Madsen PL et al. Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids. Am Heart J. 2018;203:49-56. https:\/\/doi.org\/10.1016\/j.ahj.2018.06.010","key":"ref25","DOI":"10.1016\/j.ahj.2018.06.010"},{"doi-asserted-by":"publisher","unstructured":"Marsh JD, Lehmann MH, Ritchie RH et al. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998;98(3):256-61. https:\/\/doi.org\/10.1161\/01.CIR.98.3.256","key":"ref26","DOI":"10.1161\/01.CIR.98.3.256"},{"doi-asserted-by":"publisher","unstructured":"S\u00f8ndergaard EB, Thune JJ, Gustafsson F. Characteristics and outcome of patients with heart failure due to anabolic-androgenic steroids. Scand Cardiovasc J. 2014;48(6):339-42. https:\/\/doi.org\/10.3109\/14017431.2014.976837","key":"ref27","DOI":"10.3109\/14017431.2014.976837"},{"doi-asserted-by":"publisher","unstructured":"Abdollahi F, Joukar S, Najafipour H et al. The risk of life-threatening ventricular arrhythmias in presence of high-intensity endurance exercise along with chronic administration of nandrolone decanoate. Steroids. 2016;105:106-12. https:\/\/doi.org\/10.1016\/j.steroids.2015.12.002","key":"ref28","DOI":"10.1016\/j.steroids.2015.12.002"},{"doi-asserted-by":"publisher","unstructured":"Sveinsson O, Herrman L. Cortical venous thrombosis following exogenous androgen use for bodybuilding. BMJ Case Rep. 2013;2013:bcr2012008638. https:\/\/doi.org\/10.1136\/bcr-2013-008638","key":"ref29","DOI":"10.1136\/bcr-2013-008638"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T07:00:30Z","timestamp":1747378830000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskabV04240260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":30,"URL":"https:\/\/doi.org\/10.61409\/v04240260","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}